bisoprolol has been researched along with digoxin in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 6 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bulanova, NA; Kositsyna, IV; Morozova, MN; Tereshchenko, SN; Uteshev, IuA | 1 |
| Kowey, PR | 1 |
| Auge, D; Bachmakov, I; Endress, B; Fromm, MF; Werner, U | 1 |
| González Oliva, JC; Pou Potau, M; Ramírez de Arellano Serna, M; Salas Gama, KR; Saurina i Solé, A | 1 |
| Calvert, M; Deeks, JJ; Griffith, M; Kirchhof, P; Kotecha, D; Lip, GY; Mehta, S; Slinn, G; Stanbury, M; Steeds, RP; Townend, JN | 1 |
| Bedak, O; Begic, E; Bradaric, H; Custovic, F; Durak-Nalbantic, A; Hodzic, E; Mujakovic, A; Prnjavorac, B; Zvizdic, F | 1 |
| Curfman, G | 1 |
| Bunting, KV; Calvert, MJ; Camm, AJ; Deeks, JJ; Gill, SK; Griffith, M; Haynes, S; Jones, JC; Kirchhof, P; Kotecha, D; Lip, GYH; Mehta, S; Rahimi, K; Stanbury, M; Steeds, RP; Strauss, VY; Townend, JN | 1 |
| Steurer, J | 1 |
| Kotecha, D | 1 |
| Garg, J; Gopinathannair, R; Lakkireddy, D | 1 |
| Deswal, A; Karimzad, K | 1 |
3 review(s) available for bisoprolol and digoxin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Chronic heart failure and atrial fibrilation: aspects of management].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Electric Countershock; Heart Failure; Humans; Quinidine; Randomized Controlled Trials as Topic; Sotalol; Sympatholytics; Time Factors; Vasodilator Agents | 2003 |
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Digoxin; Heart Failure; Humans; Metoprolol; Myocardial Infarction; Propanolamines; Randomized Controlled Trials as Topic | 2005 |
2 trial(s) available for bisoprolol and digoxin
| Article | Year |
|---|---|
A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Digoxin; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Research Design; Stroke; Time; United Kingdom | 2017 |
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Digoxin; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Quality of Life; Single-Blind Method; Stroke Volume | 2020 |
16 other study(ies) available for bisoprolol and digoxin
| Article | Year |
|---|---|
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein.
Topics: Adrenergic beta-Antagonists; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bisoprolol; Caco-2 Cells; Carbazoles; Carvedilol; Cyclosporins; Digoxin; Dose-Response Relationship, Drug; Drug Interactions; Humans; Propanolamines; Propranolol; Time Factors | 2006 |
[Difficult-to-treat atrial fibrillation in a patient on haemodialysis].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Atrial Fibrillation; Bisoprolol; Bradycardia; Calcium Channel Blockers; Cardiovascular Agents; Combined Modality Therapy; Digoxin; Diltiazem; Female; Humans; Hypothyroidism; Kidney Failure, Chronic; Myocardial Infarction; Pacemaker, Artificial; Renal Dialysis | 2010 |
Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bisoprolol; Case-Control Studies; Digoxin; Disease Progression; Forced Expiratory Volume; Humans; Metoprolol; Nebivolol; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Verapamil; Vital Capacity | 2019 |
Digitalis Glycosides for Heart Rate Control in Atrial Fibrillation.
Topics: Atrial Fibrillation; Bisoprolol; Digitalis Glycosides; Digoxin; Heart Rate; Humans; Patient Reported Outcome Measures; Quality of Life | 2020 |
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Digoxin; Heart Failure; Humans | 2021 |
Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation-Reply.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Digoxin; Heart Rate; Humans | 2021 |
Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Digoxin; Heart Rate; Humans; Patient Reported Outcome Measures; Quality of Life | 2021 |
In older patients with permanent AF and HF, digoxin and bisoprolol did not differ for QoL at 6 mo.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Digoxin; Heart Rate; Humans; Quality of Life | 2021 |